EA200300852A1 - Конъюгаты нейбластина с полимерами и способы их применения - Google Patents
Конъюгаты нейбластина с полимерами и способы их примененияInfo
- Publication number
- EA200300852A1 EA200300852A1 EA200300852A EA200300852A EA200300852A1 EA 200300852 A1 EA200300852 A1 EA 200300852A1 EA 200300852 A EA200300852 A EA 200300852A EA 200300852 A EA200300852 A EA 200300852A EA 200300852 A1 EA200300852 A1 EA 200300852A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- conjugates
- neiblast
- polymers
- methods
- application
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title abstract 2
- 102100026376 Artemin Human genes 0.000 abstract 3
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 101000785776 Homo sapiens Artemin Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229920001515 polyalkylene glycol Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Abstract
Заявлен вариантный полипептид нейбластина, подходящий для образования конъюгата, содержащего вариантный полипептид нейбластина, связанный с полимером, содержащим полиалкиленгликолевый компонент. Данный конъюгат имеет пролонгированную биодоступность и в предпочтительных вариантах пролонгированную биологическую активность по сравнению с немодифицированными формами или формами дикого типа нейбластина. Конъюгаты согласно изобретению имеют полезное применение при терапевтическом, а также нетерапевтическом, например диагностическом, использовании.Отчет о международном поиске был опубликован 2003.03.06.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26607101P | 2001-02-01 | 2001-02-01 | |
PCT/US2002/002319 WO2002060929A2 (en) | 2001-02-01 | 2002-01-25 | Polymer conjugates of neublastin and methods of using same |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200300852A1 true EA200300852A1 (ru) | 2004-06-24 |
EA009771B1 EA009771B1 (ru) | 2008-04-28 |
Family
ID=23013042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200300852A EA009771B1 (ru) | 2001-02-01 | 2002-01-25 | Полипептид нейбластина, способы его получения и применения |
Country Status (36)
Country | Link |
---|---|
EP (2) | EP1355936B1 (ru) |
JP (2) | JP4259868B2 (ru) |
KR (2) | KR100960063B1 (ru) |
CN (1) | CN1500095B (ru) |
AR (1) | AR035077A1 (ru) |
AT (1) | ATE365748T1 (ru) |
AU (1) | AU2002247037B2 (ru) |
BG (1) | BG66393B1 (ru) |
BR (1) | BR0206852A (ru) |
CA (1) | CA2436407C (ru) |
CY (1) | CY1106886T1 (ru) |
CZ (1) | CZ20032080A3 (ru) |
DE (1) | DE60220879T2 (ru) |
DK (1) | DK1355936T3 (ru) |
EA (1) | EA009771B1 (ru) |
EE (1) | EE05537B1 (ru) |
ES (1) | ES2289091T3 (ru) |
GE (1) | GEP20063916B (ru) |
HK (1) | HK1057759A1 (ru) |
HU (1) | HU228973B1 (ru) |
IL (2) | IL156941A0 (ru) |
IS (1) | IS2867B (ru) |
MX (1) | MXPA03006805A (ru) |
MY (1) | MY143685A (ru) |
NO (1) | NO332150B1 (ru) |
NZ (1) | NZ527863A (ru) |
PL (1) | PL211162B1 (ru) |
PT (1) | PT1355936E (ru) |
RS (1) | RS50857B (ru) |
SG (1) | SG149685A1 (ru) |
SI (1) | SI1355936T1 (ru) |
SK (1) | SK288123B6 (ru) |
TR (1) | TR200301208T2 (ru) |
UA (2) | UA100967C2 (ru) |
WO (1) | WO2002060929A2 (ru) |
ZA (1) | ZA200305733B (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060929A2 (en) * | 2001-02-01 | 2002-08-08 | Biogen, Inc. | Polymer conjugates of neublastin and methods of using same |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
AU2002250203B2 (en) * | 2001-03-28 | 2006-08-10 | Biogen Ma Inc. | Use of neublastin polypeptides for treating neuropathic pain |
CN1630530A (zh) * | 2002-01-18 | 2005-06-22 | 比奥根艾迪克Ma公司 | 聚亚烷基聚合物及其用途 |
ES2351215T3 (es) * | 2003-01-31 | 2011-02-01 | Biogen Idec Ma Inc. | Conjugados poliméricos de neublastina mutada. |
CA2522364C (en) | 2003-04-18 | 2014-12-09 | Biogen Idec Ma Inc. | Polymer-conjugated glycosylated neublastin |
WO2004108760A2 (en) * | 2003-06-10 | 2004-12-16 | Nsgene A/S | Improved secretion of neublastin |
US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
CA2577690C (en) * | 2004-08-19 | 2013-08-06 | Biogen Idec Ma Inc. | Refolding transforming growth factor beta family proteins |
SI1786454T1 (sl) | 2004-08-19 | 2010-10-29 | Biogen Idec Inc | Variante neoblastina |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
US20100056440A1 (en) * | 2006-03-01 | 2010-03-04 | Biogen Idec Ma Inc. | Compositions and methods for administering gdnf ligand family proteins |
AU2007296843C1 (en) | 2006-09-15 | 2012-08-16 | Creabilis Therapeutics S.P.A. | Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1 |
CA2685686A1 (en) * | 2007-05-01 | 2008-11-13 | Biogen Idec Ma Inc. | Neublastin polypeptides for use increasing vascularization in a tissue |
CN104023804B (zh) * | 2011-11-02 | 2017-05-24 | 弗·哈夫曼-拉罗切有限公司 | 超载和洗脱层析 |
RU2488635C1 (ru) * | 2012-03-22 | 2013-07-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития | Способ получения рекомбинантного антиангиогенного полипептида |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6472178B1 (en) * | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
WO2000034475A2 (en) * | 1998-12-09 | 2000-06-15 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
WO2002060929A2 (en) * | 2001-02-01 | 2002-08-08 | Biogen, Inc. | Polymer conjugates of neublastin and methods of using same |
-
2002
- 2002-01-25 WO PCT/US2002/002319 patent/WO2002060929A2/en active IP Right Grant
- 2002-01-25 IL IL15694102A patent/IL156941A0/xx unknown
- 2002-01-25 AU AU2002247037A patent/AU2002247037B2/en not_active Ceased
- 2002-01-25 SK SK971-2003A patent/SK288123B6/sk not_active IP Right Cessation
- 2002-01-25 TR TR2003/01208T patent/TR200301208T2/xx unknown
- 2002-01-25 UA UAA200802148A patent/UA100967C2/ru unknown
- 2002-01-25 EP EP02714792A patent/EP1355936B1/en not_active Expired - Lifetime
- 2002-01-25 UA UA2003088104A patent/UA82983C2/ru unknown
- 2002-01-25 NZ NZ527863A patent/NZ527863A/en not_active IP Right Cessation
- 2002-01-25 GE GE5240A patent/GEP20063916B/en unknown
- 2002-01-25 CZ CZ20032080A patent/CZ20032080A3/cs unknown
- 2002-01-25 KR KR1020087022638A patent/KR100960063B1/ko not_active IP Right Cessation
- 2002-01-25 PL PL372101A patent/PL211162B1/pl unknown
- 2002-01-25 RS YUP-610/03A patent/RS50857B/sr unknown
- 2002-01-25 JP JP2002561497A patent/JP4259868B2/ja not_active Expired - Fee Related
- 2002-01-25 EE EEP200300355A patent/EE05537B1/xx not_active IP Right Cessation
- 2002-01-25 AR ARP020100279A patent/AR035077A1/es not_active Application Discontinuation
- 2002-01-25 EA EA200300852A patent/EA009771B1/ru not_active IP Right Cessation
- 2002-01-25 CN CN028077539A patent/CN1500095B/zh not_active Expired - Fee Related
- 2002-01-25 DE DE60220879T patent/DE60220879T2/de not_active Expired - Lifetime
- 2002-01-25 MX MXPA03006805A patent/MXPA03006805A/es active IP Right Grant
- 2002-01-25 EP EP07110666A patent/EP1862475A1/en not_active Withdrawn
- 2002-01-25 HU HU0500637A patent/HU228973B1/hu not_active IP Right Cessation
- 2002-01-25 AT AT02714792T patent/ATE365748T1/de active
- 2002-01-25 DK DK02714792T patent/DK1355936T3/da active
- 2002-01-25 PT PT02714792T patent/PT1355936E/pt unknown
- 2002-01-25 KR KR1020037010127A patent/KR100872807B1/ko not_active IP Right Cessation
- 2002-01-25 SG SG200504719-6A patent/SG149685A1/en unknown
- 2002-01-25 ES ES02714792T patent/ES2289091T3/es not_active Expired - Lifetime
- 2002-01-25 CA CA2436407A patent/CA2436407C/en not_active Expired - Fee Related
- 2002-01-25 SI SI200230580T patent/SI1355936T1/sl unknown
- 2002-01-25 BR BR0206852-4A patent/BR0206852A/pt not_active Application Discontinuation
- 2002-02-04 MY MYPI20020368A patent/MY143685A/en unknown
-
2003
- 2003-07-15 IL IL156941A patent/IL156941A/en not_active IP Right Cessation
- 2003-07-17 IS IS6879A patent/IS2867B/is unknown
- 2003-07-24 ZA ZA2003/05733A patent/ZA200305733B/en unknown
- 2003-08-01 NO NO20033441A patent/NO332150B1/no not_active IP Right Cessation
- 2003-08-19 BG BG108111A patent/BG66393B1/bg unknown
- 2003-11-21 HK HK03108539A patent/HK1057759A1/xx not_active IP Right Cessation
-
2007
- 2007-09-21 CY CY20071101225T patent/CY1106886T1/el unknown
-
2008
- 2008-10-28 JP JP2008277469A patent/JP4423338B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200300852A1 (ru) | Конъюгаты нейбластина с полимерами и способы их применения | |
ES2128329T3 (es) | Conjugados de proteina-polietilenglicol. | |
EA200000607A1 (ru) | Конъюгаты эритропоэтина | |
FR13C0021I2 (fr) | Conjugates d'exendin-4 et leur utilisation medicale | |
NO20023315D0 (no) | G-CSF konjugater | |
EA200400962A1 (ru) | Полиалкиленгликоль с остатком для конъюгации биологически активного соединения | |
DE60313786D1 (de) | Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC1A | Change in name of an applicant in a eurasian application | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |